TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Going against popular opinion, committee pushes for delisting of cancer drugs

  • Gemma Holliani Cahya¬†

    The Jakarta Post

PREMIUM
Jakarta   /   Tue, April 9, 2019   /  06:10 pm
The Jakarta Post Image
Safety, effectiveness and affordability are the three core values of cost-effectiveness in Health Technology Assessment, committee head Sudigdo Sastroasmoro said. (Shutterstock/Kenishirotie)

For a patient suffering from a chronic illness, an extra day of life may be worth fighting for. But for a state body tasked with assessing the cost effectiveness of a drug, the issue must be examined from a different perspective, Sudigdo Sastroasmoro said in front of a hearing on March 11 with the House Commission IX, which oversees health care and employment.  Sudigdo is the chairman of the Indonesian Health Technology Assessment (HTA) committee. He was present for only on item on the agenda that Monday morning, namely to decide whether two forms of medication for metastatic colorectal cancer — Bevacizumab and Cetuximab — will be removed from the list of drugs covered under the national health insurance (JKN) scheme.  The issue has garnered nationwide attention and received backlash from patients, activists and doctors associations, such as the Indonesia Dige...